Astragaloside IV, as a potential anticancer agent

Area of Science:

• Pharmacology
• Oncology
• Traditional Chinese Medicine

Background:

• Cancer poses a growing global health challenge, with conventional treatments like surgery and chemotherapy often yielding unsatisfactory results due to side effects and drug resistance.
• Traditional Chinese Medicine (TCM) components are increasingly recognized for their potent anticancer activities.
• Astragaloside IV (AS-IV), derived from Astragalus membranaceus, is a key active compound with diverse pharmacological effects.

Purpose of the Study:

• To review the bioavailability, anticancer activity, and underlying mechanisms of Astragaloside IV (AS-IV).
• To explore the potential of AS-IV as a therapeutic agent against various malignant tumors.
• To provide insights for future research directions concerning AS-IV in cancer treatment.

Main Methods:

• Literature review focusing on studies investigating AS-IV's pharmacological properties and anticancer effects.
• Analysis of AS-IV's mechanisms of action, including modulation of reactive oxygen species, cell cycle arrest, apoptosis, and autophagy induction.
• Examination of AS-IV's impact on cancer cell proliferation, invasiveness, and metastasis in preclinical models.

Main Results:

• AS-IV demonstrates broad-spectrum anticancer activities against lung, liver, breast, and gastric cancers.
• Key mechanisms include regulating antioxidant enzymes, inducing cell cycle arrest, promoting apoptosis and autophagy, and inhibiting cancer cell proliferation, invasion, and metastasis.
• AS-IV exhibits favorable bioavailability, supporting its therapeutic potential.

Conclusions:

• Astragaloside IV (AS-IV) presents a promising natural compound for cancer therapy, offering multiple mechanisms to combat tumor progression.
• AS-IV's efficacy across various cancer types highlights its potential as a valuable agent in oncology.
• Further investigation into AS-IV is warranted to optimize its clinical application in cancer treatment.